Post-transplant Lymphoproliferative Disorder (PTLD): Infection, Cancer?

被引：0
作者：
Voorhees T.J. [1 ]
Baiocchi R.A. [1 ,2 ]
机构：
[1] Department of Internal Medicine, Division of Hematology, Ohio State University College of Medicine, 460 West 10th Avenue, Columbus, 43210, OH
[2] Division of Hematology, The Ohio State University, 320 West 10th Avenue, Columbus, 43210, OH
来源：
Current Transplantation Reports | 2016年 / 3卷 / 2期
关键词：
EBV; EBV oncogenesis; EBV transformation; Post-transplant lymphoproliferative disorder;
D O I：
10.1007/s40472-016-0102-0
中图分类号：
学科分类号：
摘要：
Post-transplant lymphoproliferative disorder encompasses a broad spectrum of lymphoid disorders that occur in immune-suppressed patients following solid or hematopoietic stem cell transplantation. The Epstein-Barr virus (EBV) is an oncogenic virus capable of transforming B lymphocytes and is associated with the pathogenesis of multiple benign and malignant lymphoproliferative disorders, including PTLD. This review outlines current knowledge of EBV pathogenesis, its role in B cell immortalization, transformation, and as an etiologic agent in lymphoproliferative disorders in immune-suppressed patients following transplantation. Here, we provide discussion incorporating infectious disease and medical oncology aspects. © 2016, Springer International Publishing AG.
引用
收藏
页码：145 / 153
页数：8
相关论文
共 106 条
[81]  
Tsai D.E., Hardy C.L., Tomaszewski J.E., Et al., Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients, Transplantation, 71, 8, pp. 1076-1088, (2001)
[82]  
Porcu P., Eisenbeis C.F., Pelletier R.P., Et al., Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration, Blood, 100, 7, pp. 2341-2348, (2002)
[83]  
Khatri V.P., Baiocchi R.A., Peng R., Et al., Endogenous CD8+ T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder, J Immunol, 163, 1, pp. 500-506, (1999)
[84]  
Rouphael B., Lankireddy S., Lazaryan A., Et al., Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder, Clin Transplant, 30, 1, pp. 60-65, (2016)
[85]  
Hartlage A.S., Liu T., Patton J.T., Et al., The Epstein-Barr virus lytic protein BZLF1 as a candidate target antigen for vaccine development, Cancer Immunol Res, 3, 7, pp. 787-794, (2015)
[86]  
Jones K., Nourse J.P., Morrison L., Et al., Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders, Blood, 116, 13, pp. 2245-2252, (2010)
[87]  
Sebelin-Wulf K., Nguyen T.D., Oertel S., Et al., Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD, Transpl Immunol, 17, 3, pp. 203-210, (2007)
[88]  
Swinnen L.J., Mullen G.M., Carr T.J., Et al., Aggressive treatment for postcardiac transplant lymphoproliferation, Blood, 86, 9, pp. 3333-3340, (1995)
[89]  
Choquet S., Trappe R., Leblond V., Et al., CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation, Haematologica, 92, 2, pp. 273-274, (2007)
[90]  
Elstrom R.L., Andreadis C., Aqui N.A., Et al., Treatment of PTLD with rituximab or chemotherapy, Am J Transplant, 6, 3, pp. 569-576, (2006)
234567891011